Co-Encapsulation of Simvastatin and Doxorubicin into pH-Sensitive Liposomes Enhances Antitumoral Activity in Breast Cancer Cell Lines
Doxorubicin (DOX) is a potent chemotherapeutic drug used as the first line in breast cancer treatment; however, cardiotoxicity is the main drawback of the therapy. Preclinical studies evidenced that the association of simvastatin (SIM) with DOX leads to a better prognosis with reduced side effects a...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2023-01-01
|
| Schriftenreihe: | Pharmaceutics |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/1999-4923/15/2/369 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|